Oral iron chelation: New drug, old rules

Blood

Volumn 111, Issue 2, 2008, Pages 483-484

  Nathan, David G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; IRON CHELATE;

ANEMIA; ENTEROHEPATIC CIRCULATION; FECES; GASTROINTESTINAL TRACT; GOLD STANDARD; IRON CHELATION; IRON OVERLOAD; LIVER; LIVER BIOPSY; LIVER FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA HALF LIFE; PRIORITY JOURNAL; SHORT SURVEY; SINGLE DRUG DOSE; URINARY EXCRETION;

EID: 38349159620     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-11-123349     Document Type: Short Survey

References (5)

1. Modell B. Total management of thalassaemia major. Arch Dis Child. 1977;52:489-500.
2. Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Lancet. 1991;337:277-280.
3. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597-602.
4. Porter JB. Practical management of iron overload. Br J Haematol. 2001;115:239-252.
5. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855-861.